The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease

British Medical Bulletin

Volumn 92, Issue 1, 2009, Pages 61-77

  Shale, Matthew J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anti TNF; Hepatitis B virus; Varicella zoster virus; Viral infection

Indexed keywords

ACICLOVIR; ADALIMUMAB; ADEFOVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; ENTECAVIR; ETANERCEPT; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INFLUENZA VACCINE; LAMIVUDINE; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; RECOMBINANT INTERFERON; RIBAVIRIN; RITUXIMAB; TENOFOVIR; TUMOR NECROSIS FACTOR INHIBITOR; VALACICLOVIR;

AWARENESS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; CONSENSUS; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; EPSTEIN BARR VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX; HERPES ZOSTER; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS MONONUCLEOSIS; INFLUENZA; JC VIRUS; LIVER CIRRHOSIS; LONG TERM CARE; LUNG ASPERGILLOSIS; LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SEROLOGY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS RESISTANCE; WART VIRUS;

CHRONIC DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; RECURRENCE; RISK; TUMOR NECROSIS FACTOR-ALPHA; VIRUS DISEASES;

EID: 72049091520     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldp036     Document Type: Review

References (54)

1. Faubion WA, Loftus EV, Harmsen WS et al. (2001) The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology, 121, 255-260.
2. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP (2005) Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut, 54, 237-241.
3. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF (2008) Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut, 57, 549-558.
4. Keane J, Gershon S, Wise RP et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor-a neutralizing agent. N Engl J Med, 345, 1098-1104.
5. Velayos FS, Sandborn WJ (2004) Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis, 10, 657-660.
6. Salliot C, Gossec L, Ruyssen-Witrand A et al. (2007) Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology, 46, 327-334.
7. Colombel JF, Loftus EV, Tremaine WJ et al. (2004) The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology, 126, 19-31.
8. Fidder H, Schnitzler F, Ferrante M et al. (2009) Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single centre cohort study. Gut, 58, 501-508.
9. Lichtenstein GR, Feagan B, Cohen RD et al. (2006) Serious infections and mortality in association with therapies for Crohn's disease: TREAT Registry. Clin Gastroenterol Hepatol, 4, 621-630.
10. Toruner M, Loftus EV, Harmsen WS et al. (2008) Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology, 134, 929-936.
11. Aberra FN, Lichtenstein GR (2005) Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis, 11, 685-695.
12. Strangfeld A, Listing J, Herzer P et al. (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA, 301, 737-744.
13. Wong GH, Goeddel DV (1986) Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature, 323, 819-822.
14. Slifkin M, Doron S, Snydman DR (2004) Viral prophylaxis in organ transplant patients. Drugs, 64, 2763-2792.
15. Skripak JM, Rodgers GL, Martucci C et al. (2003) Disseminated herpes simplex (HSV) infection precipitating macrophage activation syndrome (MAS) in a child with systemic juvenile idiopathic arthritis (SJIA) undergoing therapy with infliximab [abstract]. Pediatr Rheumatol Online J, 1, S58.
16. van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, van der Spoel JI, Wester JP, Zandstra DF (2003) Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med, 29, 2327-2329.
17. Wendling D, Streit G, Toussirot E, Prati C (2008) Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine, 75, 540-543.
18. Balato N, Gaudiello F, Balato A, Ayala F (2009) Development of primary varicella infection during infliximab treatment for psoriasis. J Am Acad Dermatol, 60, 709-710.
19. Leung VS, Nguyen MT, Bush TM (2004) Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol, 99, 2503-2504.
20. Lavagna A, Bergallo M, Daperno M et al. (2007) Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis, 13, 896-902.
21. Torre-Cisneros J, Del Castillo M, Castón JJ, Castro MC, Pérez V, Collantes E (2005) Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatology (Oxford), 44, 1132-1135.
22. D'Ovidio V, Vernia P, Gentile G et al. (2008) Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. J Clin Virol, 43, 180-183.
23. Sari I, Birlik M, Gonen C et al. (2008) Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol, 14, 2912-2914.
24. Reijasse D, Le Pendeven C, Cosnes J et al. (2004) Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. Inflamm Bowel Dis, 10, 85-90.
25. Cezard JP, Nouaili N, Talbotec C et al. (2003) A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr, 36, 632-636.
26. Shale M, Kanfer E, Panaccione R, Ghosh S (2008) Hepatosplenic T-cell lymphoma in Inflammatory bowel disease. Gut, 57, 1639-1641.
27. Loras C, Saro C, Gonzalez-Huix F et al. (2009) Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol, 104, 57-63.
28. Sakellariou GT, Chatzigiannis I (2007) Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol, 26, 950-952.
29. Montiel PM, Solis JA, Chirinos JA, Casis B, Sánchez F, Rodríguez S (2008) Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int, 28, 718-720.
30. Ojiro K, Naganuma M, Ebinuma H et al. (2008) Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol, 43, 397-401.
31. Benucci M, Manfredi M, Mecocci L (2008) Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol, 14, 245-246.
32. Robinson H, Walker-Bone K (2009) Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford), 48, 448-450.
33. Li S, Kaur PP, Chan V, Berney S (2009) Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab,etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol, 28, 787-791.
34. Cansu DU, Kalifoglu T, Korkmaz C (2008) Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol, 35, 421-424.
35. Esteve M, Loras C, González-Huix F (2007) Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis, 13, 1450-1451.
36. Zein NN, Etanercept Study Group (2005) Etanercept as an adjuvant to interferon and riba-virin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol, 42, 315-322.
37. Ferri C, Ferraccioli G, Ferrari D et al. (2008) Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol, 35, 1944-1949.
38. Peterson JR, Hsu FC, Simkin PA, Wener MH (2003) Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis, 62, 1078-1082.
39. Marotte H, Fontanges E, Bailly F, Zoulim F, Trepo C, Miossec P (2007) Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford), 46, 97-99.
40. Vauloup C, Krzysiek R, Greangeot-Keros L et al. (2006) Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw, 17, 290-293.
41. Aboulafia DM, Bundow D, Wilske K, Ochs UI (2000) Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc, 75, 1093-1098.
42. Beltrán B, Nos P, Bastida G, Iborra M, Hoyos M, Ponce J (2006) Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease. Gut, 55, 1670-1671.
43. Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD (2008) The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis, 67, 710-712.
44. Sha BE, Valdez H, Gelman RS et al. (2002) Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses, 18, 661-665.
45. Walker RE, Spooner KM, Kelly G et al. (1996) Inhibition of immunoreactive tumor necrosis factor-a by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis, 174, 63-68.
46. Wallis RS, Kyambadde P, Johnson JL et al. (2004) A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS, 18, 257-264.
47. Kane S, Khatibi B, Reddy D (2008) Higher incidence of abnormal pap smears in women with inflammatory bowel disease. Am J Gastroenterol, 103, 631-663.
48. Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN (2009) Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology, 136, 451-458.
49. Verbeeck J, Van Assche G, Ryding J et al. (2008) JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multi-focal leukoencephalopathy? Gut, 57, 1393-1397.
50. Rahier JF, Ben-Horin S, Chowers Y et al. (2009) European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis, 3, 47-91.
51. Deighton C, Ding T, Hyrich K et al. (2009) British Society for Rheumatology Rheumatoid Arthritis Biologics Guidelines (Draft Guidelines). Available online at: http://www.rheumatology.org.uk/guidelines/draftraguide (accessed 26 May).
52. Lebwohl M, Bagel J, Gelfand JM et al. (2008) From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol, 58, 94-105.
53. Melmed GY, Ippoliti AF, Papadakis KA et al. (2006) Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol, 101, 1834-1840.
54. Smith CH, Anstey AV, Barker JNWN et al. (2005) British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol, 153, 486-497.